Award
NIH Reporter #1R01AI203505-01
Intravenous administered acetalated dextran microparticles for the treatment of multiple sclerosis
Recipient
University of North Carolina at Chapel Hill
Award Amount
$530,480.00
Ceiling
$530,480.00
Awarded
August 20, 2026
Identifier
1R01AI203505-01
NIH grant awarded to develop intravenous acetalated dextran microparticles targeting B cells to induce antigen-specific tolerance as a novel treatment for multiple sclerosis.
Description
This project proposes using biopolymeric acetalated dextran (Ace-DEX) microparticles to target B cells in vivo and induce antigen-specific tolerance for treating multiple sclerosis, a chronic immune-mediated disorder of the central nervous system. Preliminary data shows promising results in mice models.